摘要:
Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Foπn II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.
摘要:
The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, (NERATINIB) methods of preparing crystalline maleate salt forms, the associated compounds, such as its degradation and impurities and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
摘要:
The present invention relates to liquid formulations of inhibitors of phospholipase enzymes, such as cytosolic PLA2, compositions containing the same and processes for manufacture thereof.
摘要:
The present invention relates to aqueous formulations of ERβ selective ligands. In some embodiments, the formulations include an ERβ selective ligand, a solubilizer/complexant component, and a pH adjusting component. The invention further provides preparations of the formulations, and uses thereof.
摘要:
The present invention provides solid dosage formulations of [1,4]diazepino[6,7,1-ij]quinoline derivatives and processes for their manufacture. In some particular embodiments, the present invention provides novel formulations of the antipsychotic and antiobesity agent (9aR, 12aS)-4,5,6,7,9,9a,10,11,12,12adecahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline hydrochloride (Compound A-HCI).
摘要:
The present invention relates to lyophilized compositions of a triazolopyrimidine compound, or a hydrate thereof, or a pharmaceutically acceptable salt of Compound I or hydrate thereof; solutions useful in preparing said lyophilized compositions; methods for preparing such compositions; methods of reconstituting the same; kits containing such compositions; and uses of the compositions for the treatment of cancer.
摘要:
Pharmaceutical formulations containing 5-cyclopropyl-2-(4- fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-l- benzofuran-3-carboxamide and pharmaceutically acceptable additives including at least one surfactant are made.
摘要:
Crystalline solid forms of tigecycline, Form I, Form II, Form III, Form IV, and Form V, compositions comprising these crystalline solid forms, and processes for preparing these crystalline solid forms are described herein.